186 related articles for article (PubMed ID: 26960538)
21. Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study.
Jakobsen JÅ; Quattrocchi CC; Müller FHH; Outteryck O; Alcázar A; Reith W; Fraga P; Panebianco V; Sampedro A; Pietura R
BMC Med Imaging; 2021 Apr; 21(1):74. PubMed ID: 33879075
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of gadobutrol versus gadopentetate dimeglumine in enhanced MRI of brain metastases.
Fan B; Li M; Wang X; Xu Y; Li F; Zhang L; Jiang J; Jiang Y
J Magn Reson Imaging; 2017 Jun; 45(6):1827-1834. PubMed ID: 27696616
[TBL] [Abstract][Full Text] [Related]
23. A Japanese, Multicenter, Open-label, Phase 3 Study to Investigate the Safety and Efficacy of Gadobutrol for Contrast-enhanced MR Imaging of the Central Nervous System.
Tanaka A; Masumoto T; Yamada H; Kurauchi M; Breuer J
Magn Reson Med Sci; 2016; 15(2):227-36. PubMed ID: 26687097
[TBL] [Abstract][Full Text] [Related]
24. Time-resolved contrast-enhanced three-dimensional pulmonary MR-angiography: 1.0 M gadobutrol vs. 0.5 M gadopentetate dimeglumine.
Fink C; Bock M; Kiessling F; Lichy MP; Krissak R; Zuna I; Schmähl A; Delorme S; Kauczor HU
J Magn Reson Imaging; 2004 Feb; 19(2):202-8. PubMed ID: 14745754
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study).
Maravilla KR; San-Juan D; Kim SJ; Elizondo-Riojas G; Fink JR; Escobar W; Bag A; Roberts DR; Hao J; Pitrou C; Tsiouris AJ; Herskovits E; Fiebach JB
AJNR Am J Neuroradiol; 2017 Sep; 38(9):1681-1688. PubMed ID: 28663267
[TBL] [Abstract][Full Text] [Related]
26. Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imaging of the central nervous system.
Gutierrez JE; Rosenberg M; Duhaney M; Simon JA; Brueggenwerth G; Agris JM; Knopp EA
J Magn Reson Imaging; 2015 Mar; 41(3):788-96. PubMed ID: 24578298
[TBL] [Abstract][Full Text] [Related]
27. Gadobutrol: A Review in Contrast-Enhanced MRI and MRA.
Scott LJ
Clin Drug Investig; 2018 Aug; 38(8):773-784. PubMed ID: 30006819
[TBL] [Abstract][Full Text] [Related]
28. Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study.
Semelka RC; Hernandes Mde A; Stallings CG; Castillo M
Magn Reson Imaging; 2013 Jan; 31(1):96-101. PubMed ID: 22898688
[TBL] [Abstract][Full Text] [Related]
29. Comparison of gadoteric acid and gadobutrol for detection as well as morphologic and dynamic characterization of lesions on breast dynamic contrast-enhanced magnetic resonance imaging.
Renz DM; Durmus T; Böttcher J; Taupitz M; Diekmann F; Huppertz A; Pfeil A; Maurer MH; Streitparth F; Bick U; Hamm B; Fallenberg EM
Invest Radiol; 2014 Jul; 49(7):474-84. PubMed ID: 24637587
[TBL] [Abstract][Full Text] [Related]
30. Gadobutrol-Enhanced Magnetic Resonance Imaging of the Breast in the Preoperative Setting: Results of 2 Prospective International Multicenter Phase III Studies.
Sardanelli F; Newstead GM; Putz B; Jirakova Trnkova Z; Trimboli RM; Abe H; Haverstock D; Rosenberg M
Invest Radiol; 2016 Jul; 51(7):454-61. PubMed ID: 26840494
[TBL] [Abstract][Full Text] [Related]
31. Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections.
McDonald JS; Hunt CH; Kolbe AB; Schmitz JJ; Hartman RP; Maddox DE; Kallmes DF; McDonald RJ
Radiology; 2019 Sep; 292(3):620-627. PubMed ID: 31264948
[TBL] [Abstract][Full Text] [Related]
32. Gadobutrol in Renally Impaired Patients: Results of the GRIP Study.
Michaely HJ; Aschauer M; Deutschmann H; Bongartz G; Gutberlet M; Woitek R; Ertl-Wagner B; Kucharczyk W; Hammerstingl R; De Cobelli F; Rosenberg M; Balzer T; Endrikat J
Invest Radiol; 2017 Jan; 52(1):55-60. PubMed ID: 27529464
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI.
Kuhl C; Csőszi T; Piskorski W; Miszalski T; Lee JM; Otto PM
Radiology; 2023 Jul; 308(1):e222612. PubMed ID: 37462494
[TBL] [Abstract][Full Text] [Related]
34. Allergic-like Reactions to the MR Imaging Contrast Agent Gadobutrol: A Prospective Study of 32 991 Consecutive Injections.
Power S; Talbot N; Kucharczyk W; Mandell DM
Radiology; 2016 Oct; 281(1):72-7. PubMed ID: 27110731
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial.
Loevner LA; Kolumban B; Hutóczki G; Dziadziuszko K; Bereczki D; Bago A; Pichiecchio A
Invest Radiol; 2023 May; 58(5):307-313. PubMed ID: 36729404
[TBL] [Abstract][Full Text] [Related]
36. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability.
Tombach B; Bremer C; Reimer P; Matzkies F; Schaefer RM; Ebert W; Geens V; Eisele J; Heindel W
AJR Am J Roentgenol; 2002 Jan; 178(1):105-9. PubMed ID: 11756100
[TBL] [Abstract][Full Text] [Related]
37. Prospective Safety Study of Intrathecal Gadobutrol in Different Doses.
Sperre A; Karsrud I; Rodum AHS; Lashkarivand A; Valnes LM; Ringstad G; Eide PK
AJNR Am J Neuroradiol; 2023 May; 44(5):511-516. PubMed ID: 37024308
[TBL] [Abstract][Full Text] [Related]
38. Peripheral magnetic resonance angiography with continuous table movement in combination with high spatial and temporal resolution time-resolved MRA With a total single dose (0.1 mmol/kg) of gadobutrol at 3.0 T.
Voth M; Haneder S; Huck K; Gutfleisch A; Schönberg SO; Michaely HJ
Invest Radiol; 2009 Sep; 44(9):627-33. PubMed ID: 19652610
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous acquisition of MR angiography and diagnostic images of abdomen at view-sharing multiarterial phases and comparing the effect of two different contrast agents.
Noda Y; Goshima S; Namimoto T; Shinkawa N; Nakagawa M; Kajita K; Kawada H; Kawai N; Tanahashi Y; Matsuo M; Bae KT; Hirai T; Yamashita Y
J Magn Reson Imaging; 2018 Jul; 48(1):102-110. PubMed ID: 29247585
[TBL] [Abstract][Full Text] [Related]
40. Toxicological safety evaluation of gadobutrol.
Wack C; Steger-Hartmann T; Mylecraine L; Hofmeister R
Invest Radiol; 2012 Nov; 47(11):611-23. PubMed ID: 23011188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
